Arvinas, Inc.
- ARVN
- NASDAQ
- Biotechnology
- Protein Degradation (PROTAC)
- Oncology Therapies
$6.97
Today −2.65%Quote Oct 16, 2026, 08:00 PM UTC
−16.13%over the last month
Max drawdown −19.9%From 1-month high −18.1%3 months −13.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$449.7M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$14.17
+103.3% from here
Floor
$6.81
2.3% below price
Where the price sits
26 analysts
Analyst range, low to high
$10.00$20.00
- Price $6.97
- Resistance $7.01
- Consensus $14.17
The price is right under resistance. Analysts' average target sits about 103% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ARVNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $246.2M
- Collaboration Agreement Revenue$133.7M54.3%
- License$62.5M25.4%
- Milestone Revenue$50.0M20.3%
Industry
Biotechnology
Employees
246
Founded
2013